Patents by Inventor Regine Kaufmann

Regine Kaufmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11389421
    Abstract: The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; and B) a rivastigmine-containing layer.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: July 19, 2022
    Assignee: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Marco Emgenbroich, Nico Reum, Jessica Verstraelen, Regine Kaufmann
  • Publication number: 20210038532
    Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising A) a backing layer, B) an active agent-containing layer comprising a therapeutically effective amount of the active agent, and C) a skin contact layer comprising at least one silicone acrylic hybrid polymer.
    Type: Application
    Filed: March 11, 2019
    Publication date: February 11, 2021
    Inventors: Marco EMGENBROICH, Gabriel WAUER, Michael LINN, Rolf BÖHM, Christoph SCHMITZ, Regine KAUFMANN, Hans-Wemer WOLF, Nico REUM, Anna SCHLÜTER
  • Publication number: 20210008000
    Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising A) a backing layer, B) an active agent-containing layer, wherein the active agent-containing layer comprises a therapeutically effective amount of the active agent and at least one silicone acrylic hybrid polymer, and C) a skin contact layer.
    Type: Application
    Filed: March 11, 2019
    Publication date: January 14, 2021
    Inventors: Marco EMGENBROICH, Gabriel WAUER, Michael LINN, Rolf BÖHM, Christoph SCHMITZ, Regine KAUFMANN, Hans-Wemer WOLF, Nico REUM, Anna SCHLÜTER
  • Publication number: 20210000756
    Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising A) a backing layer, B) an active agent-containing layer, wherein the active agent-containing layer comprises a therapeutically effective amount of the active agent and at least one silicone acrylic hybrid polymer, and C) a skin contact layer, wherein the skin contact layer comprises at least one silicone acrylic hybrid polymer.
    Type: Application
    Filed: March 11, 2019
    Publication date: January 7, 2021
    Inventors: Marco EMGENBROICH, Gabriel WAUER, Michael LINN, Rolf BÖHM, Christoph SCHMITZ, Regine KAUFMANN, Hans-Werner WOLF, Nico REUM, Anna SCHLÜTER
  • Publication number: 20200261394
    Abstract: The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; and B) a rivastigmine-containing layer.
    Type: Application
    Filed: September 4, 2018
    Publication date: August 20, 2020
    Inventors: Marco EMGENBROICH, Nico REUM, Jessica VERSTRAELEN, Regine KAUFMANN
  • Publication number: 20190298662
    Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 3, 2019
    Inventors: René EIFLER, Michael HORSTMANN, Regine KAUFMANN, Patrick MOHR, Eric GALIA, Wolfgang PRANGE, Stefan BULLER, Klaus PUSECKER, Jan STAMPFUSS, Susanne STOELBEN
  • Patent number: 10363228
    Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: July 30, 2019
    Assignees: LTS Lohmann Therapie-Systeme AG, Gruenenthal GmbH
    Inventors: René Eifler, Michael Horstmann, Regine Kaufmann, Patrick Mohr, Eric Galia, Wolfgang Prange, Stefan Buller, Klaus Pusecker, Jan Stampfuss, Susanne Stoelben
  • Patent number: 9833418
    Abstract: The present invention relates to transdermal therapeutic systems that include an occlusive back layer impervious to an active substance, a single or multilayer matrix, and a peelable protective film. The matrix or at least one of the matrix layers includes a pharmaceutical active substance or a plurality of pharmaceutical active substances in the form of at least one pharmaceutically consumable salt thereof and a pharmaceutically consumable, alkaline reacting oxide.
    Type: Grant
    Filed: May 19, 2010
    Date of Patent: December 5, 2017
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: René Eifler, Regine Kaufmann, Patrick Mohr
  • Publication number: 20120225103
    Abstract: This invention relates to a transdermal therapeutic system (TTS) releasing an active pramipexol agent during a time ranging from 4 to 7 days.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 6, 2012
    Inventors: Frank THEOBALD, Wolfgang LAUX, Beatrix PLATT, Regine KAUFMANN
  • Publication number: 20120065599
    Abstract: The present invention relates to transdermal therapeutic systems that include an occlusive back layer impervious to an active substance, a single or multilayer matrix, and a peelable protective film. The matrix or at least one of the matrix layers includes a pharmaceutical active substance or a plurality of pharmaceutical active substances in the form of at least one pharmaceutically consumable salt thereof and a pharmaceutically consumable, alkaline reacting oxide.
    Type: Application
    Filed: May 19, 2010
    Publication date: March 15, 2012
    Inventors: René Eifler, Regine Kaufmann, Patrick Mohr
  • Publication number: 20110313372
    Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.
    Type: Application
    Filed: June 17, 2011
    Publication date: December 22, 2011
    Inventors: René EIFLER, Michael Horstmann, Regine Kaufmann, Patrick Mohr
  • Publication number: 20060182791
    Abstract: The invention relates to a transdermal therapeutic system (TTS) releasing an active pramipexol agent during a time ranging from 4 to 7 hours.
    Type: Application
    Filed: July 14, 2004
    Publication date: August 17, 2006
    Inventors: Frank Theobald, Wolfgang Laux, Beatrix Platt, Regine Kaufmann